Key result
The CYP2C19 *2/*2 genotype was an independent risk factor for multi-site atherosclerosis compared to the *1/*1 genotype (OR 1.767; 95% CI 1.091-2.864; P=0.021).
Why the study?
Atherosclerosis frequently affects multiple organs with genetic factors contributing to risk, prompting investigation into the relationship between CYP2C19 polymorphisms and multi-site atherosclerosis.
Does the CYP2C19 *2/*2 genotype increase the risk of multi-site atherosclerosis compared to the *1/*1 genotype?
Cohort (n=939)
Does the CYP2C19 *2/*2 genotype increase the risk of multi-site atherosclerosis compared to the *1/*1 genotype?
Odds Ratio: 1.767 (95% CI 1.091–2.864)
p-value: p=0.021
The CYP2C19 *2/*2 genotype is an independent risk factor for multi-site atherosclerosis, whereas the *1/*3 genotype appears to be protective.
CYP2C19 variants may associate with multi-site atherosclerosis; leaves open whether genotyping aids risk stratification in practice.
Background: Vascular diseases such as atherosclerosis usually affect multiple organs. Genetic factors have a certain proportion in the risk factors of atherosclerosis. The purpose was to investigate the relationship of cytochrome P450 2C19 ( CYP2C19 ) polymorphisms with multi-site atherosclerosis. Methods: The study included 410 patients with single-site atherosclerosis and 529 patients with multi-site atherosclerosis. The relationship between CYP2C19 rs4244285 and rs4986893 polymorphisms and single-site atherosclerosis and multi-site atherosclerosis was analyzed. Results: The proportion of CYP2C19 rs4244285 A allele (35.9% vs 29.9%, P =0.007) and rs4986893 G allele (97.7% vs 94.8%, P =0.001) in multi-site atherosclerosis group was significantly higher than that in single-site atherosclerosis group. The distribution of CYP2C19 genotypes was significantly different between the two groups ( P =0.002). The results of univariate logistic regression indicated that CYP2C19 *1/*3 genotype (*1/*3 vs *1/*1: odds ratio (OR) 0.456, 95% confidence interval (CI): 0.231– 0.902, P =0.024) may decrease risk of multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.780, 95% CI: 1.100– 2.880, P =0.019) may increase risk of multi-site atherosclerosis. Multivariate logistic regression (adjusted for gender, age, smoking, drinking, hypertension, and diabetes) indicated that CYP2C19 *1/*3 genotype (*1/*3 vs *1/*1: OR 0.459, 95% CI: 0.231– 0.909, P =0.026) may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype (*2/*2 vs *1/*1: OR 1.767, 95% CI: 1.091– 2.864, P =0.021) may be an independent risk factor for multi-site atherosclerosis. Conclusion: CYP2C19 *1/*3 genotype may be an independent protective factor for multi-site atherosclerosis, while *2/*2 genotype may be an independent risk factor for multi-site atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2023) conducted a cohort in Atherosclerosis (n=939). CYP2C19 *2/*2 genotype vs. CYP2C19 *1/*1 genotype was evaluated on Multi-site atherosclerosis (OR 1.767, 95% CI 1.091-2.864, p=0.021). The CYP2C19 *2/*2 genotype was an independent risk factor for multi-site atherosclerosis compared to the *1/*1 genotype (OR 1.767; 95% CI 1.091-2.864; P=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: